Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» liver disease
liver disease
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
Motley Fool
Novo Nordisk
Ozempic
diabetes
weight loss
liver disease
addiction
cardiovascular disease
Flag link:
Genethon’s Gene Therapy for Rare Liver Disease Shows Promising Early-Stage Results
Genethon’s Gene Therapy for Rare Liver Disease Shows Promising Early-Stage Results
BioSpace
Genethon
gene therapy
Crigler-Najjar Syndrome
liver disease
clinical trials
Flag link:
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
Flag link:
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use
Fierce Pharma
Ipsen
Bylvay
Albireo Pharma
M&A
FDA
liver disease
Flag link:
Mallinckrodt secures FDA approval — but not without warning
Mallinckrodt secures FDA approval — but not without warning
Endpoints
Mallinckrodt
FDA
terlipressin
Terlivaz
liver disease
hepatorenal syndrome
Flag link:
Vertex, Verve team up to develop a gene editing drug for liver disease
Vertex, Verve team up to develop a gene editing drug for liver disease
Biopharma Dive
Vertex Pharma
Verve Therapeutics
liver disease
Flag link:
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference
BioSpace
EASL
liver disease
Ascletis
Takeda
Arrowhead Pharmaceuticals
Flag link:
Laekna Therapeutics Raises $61 Million in Series D financing
Laekna Therapeutics Raises $61 Million in Series D financing
BioSpace
Laekna Therapeutics
funding
liver disease
cancer
Flag link:
Intercept sells international rights to liver drug in $400M deal
Intercept sells international rights to liver drug in $400M deal
BioPharma Dive
Intercept Pharma
Advanz Pharma
Ocaliva
liver disease
Flag link:
89bio gains a little more confidence in NASH treatment with new hormone data
89bio gains a little more confidence in NASH treatment with new hormone data
Fierce Biotech
89Bio
NASH
liver disease
pegozafermin
Flag link:
Digital health firm ChronWell raises $6m for liver disease toolkit
Digital health firm ChronWell raises $6m for liver disease toolkit
Pharmaforum
ChronWell
liver disease
digital health
digital therapeutics
patient managment
Flag link:
CRISPR-editing biotech Arbor Bio adds $215M for liver, CNS disease therapies
CRISPR-editing biotech Arbor Bio adds $215M for liver, CNS disease therapies
MedCity News
Arbor Biotechnologies
MIT
liver disease
CNS disorders
funding
CRISPR
Flag link:
Genevant, Takeda Enter Collab to Find a Cure for Rare Liver Diseases
Genevant, Takeda Enter Collab to Find a Cure for Rare Liver Diseases
BioSpace
Genevant Sciences
Takeda
liver disease
drug development
Flag link:
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit
Pharmaforum
Novo Nordisk
Dicerna
gene silencing
liver disease
Flag link:
Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Fierce Biotech
Dyno
Roche
Spark Therapeutics
gene therapy
liver disease
CNS
Flag link:
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug
Xconomy
Arrowhead Pharmaceuticals
clinical trials
liver disease
RNAi
ARO-AAT
Flag link:
Mirum Pharmaceuticals Files for $63 Million Offering
Mirum Pharmaceuticals Files for $63 Million Offering
CP WIre
Mirum Pharmaceuticals
liver disease
Flag link:
Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform
Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform
Endpoints
Dicerna
Novo Nordisk
liver disease
RNAi
Flag link:
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Motley Fool
liver disease
NASH
The Liver Meeting
Assembly Biosciences
CymaBay Therapeutics
Madrigal Pharmaceuticals
Flag link:
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
Endpoints
Mirum
IPOs
Shire
liver disease
Flag link:
Pages
1
2
3
next ›
last »